Global Cord Blood logo

CO - Global Cord Blood Share Price

$3.5 0.1  3.2%

Last Trade - 18/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £317.7m
Enterprise Value £-315.8m
Revenue £140.1m
Position in Universe 3112th / 6371
Bullish
Bearish
Unlock CO Revenue
Momentum
Relative Strength (%)
1m -5.07%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -41.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
635.1 663 760 936.8 986.8 1,221 1,638 1,922 +14.0%
-15.1 -2.8 +22.6 +22.8 +20.7 +61.5
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 30 June 2020, Global Cord Blood Corp revenues increased 3% to RMB280.9M. Net income increased 22% to RMB132.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from FV Adjustments of Financial Investments increase of 84% to RMB18.4M (income), Sales and Marketing decrease of 9% to RMB55.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CO
Graphical History

Revenue

CO Revenue Unlock CO Revenue

Net Income

CO Net Income Unlock CO Revenue

Normalised EPS

CO Normalised EPS Unlock CO Revenue

PE Ratio Range

CO PE Ratio Range Unlock CO Revenue

Dividend Yield Range

CO Dividend Yield Range Unlock CO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CO EPS Forecasts Unlock CO Revenue
Profile Summary

Global Cord Blood Corporation, formerly China Cord Blood Corporation, is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People's Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. It also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. The Company provides cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies, such as cord blood transplants. It also preserves cord blood units donated by the public; provides matching services on such donated units, and delivers matching units to patients in need of transplants.

Directors
Last Annual March 31st, 2020
Last Interim June 30th, 2020
Incorporated April 10, 2006
Public Since November 19, 2009
No. of Shareholders: n/a
No. of Employees: 1,260
Sector Healthcare
Industry Healthcare Providers & Services
Index
Exchange New York Stock Exchange
Shares in Issue 121,551,075
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CO
Upcoming Events for CO
Frequently Asked Questions for Global Cord Blood
What is the Global Cord Blood share price?

As of 18/09/20, shares in Global Cord Blood are trading at $3.5, giving the company a market capitalisation of £317.7m. This share price information is delayed by 15 minutes.

How has the Global Cord Blood share price performed this year?

Shares in Global Cord Blood are currently trading at $3.5 and the price has moved by -25.82% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Global Cord Blood price has moved by -34.12% over the past year.

What are the analyst and broker recommendations for Global Cord Blood?

Of the analysts with advisory recommendations for Global Cord Blood, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Global Cord Blood is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Global Cord Blood next release its financial results?

Global Cord Blood is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Global Cord Blood dividend yield?

Global Cord Blood does not currently pay a dividend.

Does Global Cord Blood pay a dividend?

Global Cord Blood does not currently pay a dividend.

When does Global Cord Blood next pay dividends?

Global Cord Blood does not currently pay a dividend.

How do I buy Global Cord Blood shares?

To buy shares in Global Cord Blood you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Global Cord Blood?

Shares in Global Cord Blood are currently trading at $3.5, giving the company a market capitalisation of £317.7m.

Where are Global Cord Blood shares listed? Where are Global Cord Blood shares listed?

Here are the trading details for Global Cord Blood:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: CO
What kind of share is Global Cord Blood?

Based on an overall assessment of its quality, value and momentum, Global Cord Blood is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Global Cord Blood share price forecast 2020?

Shares in Global Cord Blood are currently priced at $3.5. At that level they are trading at 0.342% discount to the analyst consensus target price of 0.00.

How can I tell whether the Global Cord Blood share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Global Cord Blood. Over the past six months, the relative strength of its shares against the market has been -33.91%. At the current price of $3.5, shares in Global Cord Blood are trading at -8.06% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Global Cord Blood PE Ratio?

The Global Cord Blood PE ratio based on its reported earnings over the past 12 months is 5.63. The shares are currently trading at $3.5.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Global Cord Blood?

Global Cord Blood's management team is headed by:

Ting Zheng - CHM
Albert Chen - CFO
Mark Chen - NID
Ken Lu - NID
Rui Arashiyama - CEX
Xin Xu - CTO
Ping Xu - NED
Jack Chow - NID
Siu Chuen Cheng - NID
Who are the major shareholders of Global Cord Blood?

Here are the top five shareholders of Global Cord Blood based on the size of their shareholding:

Blue Ocean Structure Investment Company Ltd Corporation
Percentage owned: 65.43% (79.5m shares)
Jayhawk Capital Management, L.L.C. Hedge Fund
Percentage owned: 9.85% (12.0m shares)
Magnum Opus International (PTC), Ltd. Corporation
Percentage owned: 5.44% (6.61m shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 3.14% (3.82m shares)
Rock Springs Capital Management LP Hedge Fund
Percentage owned: 0.76% (925k shares)
Similar to CO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.